| Revista: | Jornal brasileiro de patologia e medicina laboratorial |
| Base de datos: | PERIÓDICA |
| Número de sistema: | 000297140 |
| ISSN: | 1676-2444 |
| Autors: | Sales, Alexandre de Oliveira1 Rodrigues, Sarah Jane de Paiva2 Bacchi, Carlos E3 |
| Institucions: | 1Hospital Universitario Onofre Lopes, Natal, Rio Grande do Norte. Brasil 2Universidade Federal do Rio Grande do Norte, Departamento de Patologia, Natal, Rio Grande do Norte. Brasil 3Universidade Estadual Paulista "Julio de Mesquita Filho", Faculdade de Medicina, Botucatu, Sao Paulo. Brasil |
| Any: | 2004 |
| Període: | Ago |
| Volum: | 40 |
| Número: | 4 |
| Paginació: | 265-271 |
| País: | Brasil |
| Idioma: | Portugués |
| Tipo de documento: | Artículo |
| Enfoque: | Caso clínico, analítico |
| Resumen en inglés | INTRODUCTION: The overexpression of human epidermal growth factor receptor (HER-2/neu) protein and the amplification of its gene are indicators of more aggressive behavior in breast cancer. The Food and Drug Administration (FDA) has approved HercepTest® with the goal of selecting patients to be elegible for treatment with the humanized murine monoclonal antibody anti-HER-2/neu (trastuzumab). AIMS: The aim of the present study was to compare the results of HER-2/neu expression using routine immunohistochemistry method LSAB®+ (Dakocytomation polyclonal antibody A0485) and HercepTest®. MATERIAL AND METHODS: 50 cases of breast carcinoma previously evaluated for HER-2/neu expression by routine immunohistochemistry using the LSAB+ method were included. These cases were also evaluated for HER-2/neu expression using HercepTest® for comparison. Results: 34 cases of breast carcinoma were negative for HER-2/neu expression by the two methods, with score 0 by HercepTest®. In 12 and 22 cases, respectively, score 1+ and 0 were observed by the LSAB®+ method. In eight cases, score 2+ was present by both methods. Score 3+ was found in eight cases also by both methods. DISCUSSION: The most common method used in routine clinical practice to determine HER-2/neu status is immunohistochemistry. Variability of HER-2/neu results can be caused by a number of variables including time of fixation, methods of epitope retrieval and type of primary antibodies used. CONCLUSION: The conclusion of the present study was that LSAB®+ and HercepTest® revealed equivalent results for HER-2/neu expression in breast carcinoma |
| Resumen en portugués | CONCLUSÃO: O presente estudo concluiu que o método HercepTest®demonstrou resultados equivalentes aos resultados obtidos pelo método LSAB®+ em carcinoma de mama |
| Disciplines | Medicina |
| Paraules clau: | Ginecología y obstetricia, Oncología, Inmunología, Mama, Carcinoma, Inmunohistoquímica, HER-2/neu, C-erbB-2, Estudio comparativo, Immunohistochemistry |
| Keyword: | Medicine, Gynecology and obstetrics, Oncology, Breast, HER-2/neu, C-erbB-2, Comparative studies, Immunology |
| Text complet: | Texto completo (Ver HTML) |
